Silexion Therapeutics Corp

Silexion Therapeutics is a pioneering clinical-stage oncology-focused biotechnology company engaged in discovering and developing proprietary treatments for KRAS-driven cancers. The companys platform technology is addressing difficult-to-treat solid tumors. Silexions lead product candidate, SIL-204, consists of locally administered small interfering RNAs, or siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients combined with standard-of-care chemotherapy. SIL-204 is a siRNA product candidate following Phase 1 and Phase 2 clinical trials with Silexions first-generation siG12D-LODER, also referred to as LODERTM. Results from the LODERTM Phase 2 clinical trial showed a trend for differences between treatment groups with...

Silexion therapeutics corp operates in the Biotechnology research industry.

Silexion therapeutics corp's revenue is 11m - 100m

Silexion therapeutics corp has 11 - 50 employees.